Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 20/20 | 0.68 |
| ▸ | DRD3 | P35462 | 19/20 | 0.68 |
| ▸ | DRD2 | P14416 | 16/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378290 | 1.00 | KCNH2 (0.68) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL4396531 | 1.00 | KCNH2 (0.68) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL378977 | 0.99 | KCNH2 (0.67) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL378314 | 0.87 | KCNH2 (0.84) | KCNH2DRD3DRD2CYP1A2 | |
| SCHEMBL11915309 | 0.87 | KCNH2 (0.80) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL378602 | 0.87 | KCNH2 (0.80) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL11911823 | 0.87 | KCNH2 (0.80) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL11911820 | 0.87 | KCNH2 (0.79) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL11914545 | 0.87 | KCNH2 (0.79) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL378375 | 0.87 | KCNH2 (0.79) | KCNH2DRD3DRD2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745040-A1 | AZABICYCLO(3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-01-24 | — | — | EP | claimed |
| WO-2005080382-A1 | AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | claimed |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | ADH1C, PKD1, HTT | KCNH2 3743/4885DRD3 152/4885DRD2 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.